Adrenalectomy has been recognised as the treatment of choice for adrenal tumours. However, excision of large tumours with or without vena caval tumour thrombi is difficult. The purpose of this case series was to describe the use of 3D conformal hypofractionated radiotherapy for unresectable adrenal tumours (over 7 cm long) in three dogs (bulldog, shih tzu and miniature dachshund). The tumours had invaded the caudal vena cava in two of the dogs. The irradiation protocols included 23.7 Gy/three fractions/three weeks or 26 Gy/four fractions/four weeks. Following the treatment, tumours in two cases showed a 34 and 40 per cent reduction in size. No radiation-related adverse events were detected. Metastatic lesions developed in all cases. The overall survival in the three dogs was 19, 25 and 27 months. Therefore, 3D conformal hypofractionated radiotherapy can treat adrenal tumours without severe complications, and prolong the survival in dogs.

The preparation of modified Mohs paste, commonly used for malignant wounds, requires time and effort. Moreover, metal-containing liquid waste is generated when malignant wounds are scrubbed. Therefore, we previously changed the base material of the modified Mohs paste from zinc oxide starch powder to carboxymethyl cellulose (CMC). The novel modified Mohs paste based on CMC (moM-CMC sol) may reduce these disadvantages. In the present study, the moM-CMC sol was applied to malignant tumors in three dogs to manage bleeding and malodor. The moM-CMC sol transitioned into a gel on the tumors within an hour of application and could be easily removed. The symptoms resolved in all cases. The moM-CMC sol could be beneficial for dogs with malignant wounds.

The authors present a rare case of treatment complications in a 12-year-old spayed female Shiba Inu with left nasal transitional cell carcinoma. To control the tumour, the authors performed hypofractionated radiotherapy for five fractions over 1 week, combined with surgery, acridine orange photodynamic therapy (AO-PDT) and cribriform irradiation, one month after the initial radiotherapy. Six months later, the dog presented with neurological abnormalities (circling, pacing and reduced consciousness). Pneumocephalus was diagnosed. The irradiated left side of the olfactory bulb had become necrotic; therefore, surgery was performed to close the hole of the cribriform plate. Two years later, no visible radiation side effects or clinical signs related to intranasal tumour recurrence were detected. This case suggests that hypofractionated radiotherapy followed by surgery, AO-PDT and cribriform irradiation can contribute to tumour control. However, rare side effects, such as pneumocephalus, should be considered. Therefore, patients should be monitored carefully for adverse events after this combination.

作り置き可能なカルボキシメチルセルロースを基剤としたMohs ペーストによる犬猫の自壊皮膚腫瘤の治療Storable carboxymethyl cellulose-based Mohs' paste for canine and feline malignant skin wounds

Tegafur is a prodrug of fluoropyrimidine 5-fluorouracil (5-FU), while TS-1 TM is an oral fixed-dose combination of three active drugs, tegafur, gimeracil, and oteracil. This pilot study evaluated the safety of tegafur/gimeracil/oteracil in the treatment of cancers in dogs. Tegafur/gimeracil/oteracil was administered orally at a mean dose of 1.1 mg/kg twice daily on alternate days, Monday-Wednesday-Friday, every week to 11 dogs with tumors. Partial response and stable disease were observed in one dog each, whereas six exhibited progressive disease. Three dogs were not assessed. Adverse events, the most serious being grade 2, were noted in seven dogs. Adverse events were acceptable, and the drug was effective in some dogs. Therefore, tegafur/gimeracil/oteracil may be useful for treating malignant solid tumors in canines.